GLANDGland Pharma Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why buy
- • Revenue growth: 22.3% YoY
- • Profit growth: 96.4% YoY
- • Debt/Equity: 0.03
- • RSI: 58
- • Price vs EMA21: above
- • Price vs SMA50: above
- • Pullback to 21-EMA signal (setup quality 80%)
Bull case
- • Revenue growth: 22.3% YoY
- • Profit growth: 96.4% YoY
- • Debt/Equity: 0.03
- • RSI: 58
Bear case
- • ROE: 10.5%
- • Dividend yield: 0.66%
- • MACD: bearish
- • Volume: 0.7x 20-day average
Key risks
- • ROE: 10.5%
- • Dividend yield: 0.66%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹91.09). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.